Spectral Diagnostics (OTCMKTS:EDTXF) Stock Price Up 0.4% – Should You Buy?

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) rose 0.4% on Wednesday . The stock traded as high as $0.9998 and last traded at $0.99. Approximately 30,900 shares traded hands during trading, an increase of 612% from the average daily volume of 4,337 shares. The stock had previously closed at $0.9860.

Spectral Diagnostics Stock Performance

The firm has a market cap of $290.51 million, a price-to-earnings ratio of -9.90 and a beta of 0.09. The firm has a 50-day moving average price of $1.01 and a two-hundred day moving average price of $0.98.

Spectral Diagnostics (OTCMKTS:EDTXF) last issued its earnings results on Friday, May 8th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). The business had revenue of $0.64 million for the quarter, compared to analyst estimates of $0.54 million.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.